Provenge is a first in the medical field – a therapeutic vaccine for cancer. Its maker, Dendreon, sought Food and Drug Administration (FDA) approval of Provenge from 2005 to 2010, conducting clinical trials since at least 2002. In 2007, the company was told that they still lacked data, and the FDA wanted survival statistics. They found that use of the vaccine added 4 months to the lifespan of men with advanced prostate cancer. On April 29, 2010, the FDA finally approved Provenge for the treatment of metastatic castration-resistant (hormone refractory) prostate cancer, an advanced form of the disease.

Get more facts about the prostate cancer vaccine, which uses a patient's white blood cells to prolong their life.

No comments: